benzeneacetamide (U-69,593) displaced [ 3 H]diprenorphine from three independent binding sites; these included highaffinity ␦-and -OPR sites, and a residual binding site. Residual [ 3 H]diprenorphine binding was displaced by the selective -OPR antagonist nor-binaltorphimine after saturation of ␦ and sites, respectively, with DPDPE and U-69,593. The residual binding site displayed low affinity for ␦-and -OPR agonists and TIPP, as well as moderate affinity for naltrexone-derived ligands, properties reminiscent of ␦-/-OPR heterodimers.
Opioid agonists, including morphine and loperamide, have medically important antisecretory and antipropulsive effects in the intestinal tract (Mancini and Bruera, 1998) . Their actions are due in part to hyperpolarization of enteric neurons and inhibition of neurotransmitter release and are mediated by opioid receptors (OPRs) expressed on a subpopulation of neurons in the submucosal and myenteric plexuses. Neurons within these plexuses form an intricate network of repeating circuits, which are capable of orchestrating specific responses to a variety of stimuli while remaining in constant communication with neighboring neural networks (Kunze and Furness, 1999) . The pharmacological properties of neuronal opioid receptors may, in some respects, be more amenable to study in less complex enteric neural networks than in experimental models involving the central nervous system (Kosterlitz and Waterfield, 1975) .
In studies of opioid receptors in the central nervous system, -, ␦-, and -OPR types seem to manifest additional heterogeneity (Gutstein and Akil, 2001 ). In the case of ␦-OPRs, for example, subtype-selective agonists, the absence of cross-tolerance between these agonists, and subtype-selective antagonists of both competitive and noncompetitive natures have been used in behavioral studies to distinguish putative ␦ 1 -and ␦ 2 -OPR subtypes (Zaki et al., 1996) . The molecular basis of these subtypes is unknown; however, the presence of OPR mRNA splice variants (Abbadie et al., 2001) and evidence that these receptors form homo-and heterodimeric associations in recombinant systems (Jordan and Devi, 1999; Ramsay et al., 2002) are among the variables that may contribute to their distinctive pharmacological profiles in vivo. Indeed, a recent pharmacological study suggests that ␦ 1 -OPRs in the mouse spinal cord may represent ␦-/-OPR heterodimers (Portoghese and Lunzer, 2003) , a conclusion supported by the colocalization of ␦-and -OPR immunoreactivities in a population of murine spinal axons (Wessendorf and Dooyema, 2001) . Although these limited pharmacological and immunohistochemical approaches suggest that OPR heterodimers are expressed in vivo, definitive proof is lacking.
The existence of OPR heterodimers has been documented in recombinant systems with cloned OPRs detected with fluorescent or immunological tags. Because this technique is not feasible in studies of native OPRs, alternative methods must be used for the detection of the receptor complexes in tissues, a critical step in determining the physiological significance of these OPR associations. Ligand binding studies performed in recombinant systems containing heterodimeric OPRs reveal a mix of the binding characteristics of each receptor constituent (Maggio et al., 1993; Jordan and Devi, 1999) . Membrane homogenates from native tissues are often heterogeneous, a fact that complicates the analysis of binding assays; these membrane preparations may contain both monomeric and heterodimeric receptor populations, from separate cells or distinct domains from within a single cell.
Neural membrane preparations from the myenteric plexus of the porcine small intestine express specific ␦-and -OPR binding sites, but relatively few -OPR sites (Townsend and Brown, 2002) . Immunoreactivities for ␦-and -OPRs, but not -OPRs are expressed in myenteric neurons and are colocalized in some cells (Poonyachoti et al., 2001 (Poonyachoti et al., , 2002 . Moreover, neurogenic contractions of a smooth muscle-myenteric plexus preparation from the porcine ileum are inhibited by agonists acting selectively at either ␦-or -OPRs, although the actions of a ␦-OPR agonist can be prevented by nor-binaltorphimine (nor-BNI), a selective -OPR antagonist (Poonyachoti et al., 2001) . These results suggest that some myenteric neurons may express functional ␦-and -OPRs and that some of these receptors might be in association. In the present study, we characterized in detail the ␦-and -OPR binding sites in myenteric neural membranes. The binding affinities of selective OPR ligands in displacing the poorly selective opioid antagonist [
3 H]diprenorphine (DPN) from these sites were determined and compared in Na ϩ -free and physiologically relevant solutions. In addition, we examined a residual nor-BNI binding site that was revealed after agonist saturation of ␦ and sites. 5␣, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 70 Ci/mmol] were obtained from Amersham Biosciences Inc. (Piscataway, NJ) and PerkinElmer Life Sciences (Boston, MA), respectively. Both radioligands were diluted to the desired concentration in 5 mM HCl and stored at Ϫ20°C until use. Naloxone, tetrodotoxin, D-(5␣,7␣,8␤)-(Ϫ)-N-methyl-N-(7-(1-pyrrolidinyl)-1-oxoaspiro-(4,5)dec-8-yl)benzeneacetamide (U-69,593), and
Materials and Methods

Radioligands
Glu 4 ]deltorphin II, and Tyr-1,2,3,4-tetrahydroisoquinoline-Phe-Phe-OH (TIPP) were obtained from Bachem (Torrance, CA). Naltriben (NTB), 7-benzylidenenaltrexone (BNTX), naltrindole (NTI), 5Ј-guanidinonaltrindole (GNTI), and nor-BNI were synthesized in the laboratory of P.S.P. as reported previously (Portoghese et al., 1988 (Portoghese et al., , 1991 Jones et al., 1998 , and 25.0 mM HEPES); the pH of both buffers was corrected to 7.4 by the addition of 6 M HCl. The P2 membrane fractions were isolated as described previously in either Tris or Krebs-HEPES buffer (Townsend and Brown, 2002) from smooth muscle-myenteric plexus homogenates; the P2 membrane fraction was enriched in specific [
3 H]STX binding sites (see below) and is henceforth referred to as the "neural membrane" fraction. After isolation, membrane fractions were stored at Ϫ70°C until binding assays were performed. Protein concentrations were determined with a bicinchoninic acid protein assay kit (Pierce Chemical, Rockford, IL).
SDS-Polyacrylamide Gel Electrophoresis and Western Blotting. Equivalent amounts of crude membrane proteins were resolved by nonreducing 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were then transferred to Immobilon membranes (Millipore Corporation, Billerica, MA) and blocked with 5% milk in wash solution (10 mM Tris and 150 mM NaCl and 0.05% Tween 20). Blots were incubated for 4 h with an antiserum raised in goats against human growth-associated protein (GAP)-43, a neuronal marker (Santa Cruz Biotechnology Inc., Santa Cruz, CA) that was diluted 1:1000 in the blocking solution. After blots were washed three times (for 15, 5, and 5 min, respectively) with wash solution, they were incubated in horseradish peroxidase-conjugated anti-goat IgG (1:5000) for 2 h. After one 15 min and four 5-min washes, the blots were developed using an enhanced chemiluminescence detection system (Amersham, Piscataway, NJ).
Radioligand Binding Assays. Neural membranes were thawed on ice just before each experiment and diluted to a final concentration of 500 g/ml in either Tris or Krebs-HEPES buffer. Actual protein concentrations were determined from single aliquots of the diluted membrane fraction used in each assay. Specific binding sites for the neuronal Na ϩ channel blocker STX were detected through the binding of 1 nM [ 3 H]STX to membranes in the absence and presence of 1 M of unlabeled tetrodotoxin. Saturation analyses of specific OPR binding sites were performed using the poorly selective OPR antagonist DPN (0.03-3 nM); nonspecific binding was determined in the presence of 1 M unlabeled naloxone. The binding affinities of various OPR ligands were determined by their displacement of 1 nM [ 3 H]DPN from specific binding sites. All displacement assays were initiated by the addition of membranes to tubes containing radioligand in the absence or in combination with an unlabeled ligand. To ensure that equilibrium conditions were achieved, assays were allowed to incubate for 60 min at room temperature before rapid filtration of unbound ligands through glass fiber filters using a 24-sample cell harvester (Brandel, Inc., Gaithersburg, MD). Glass fiber filters were then washed twice with 4 ml of cold Tris or Krebs-HEPES buffer and subsequently submerged in scintillation fluid for approximately 12 h before being counted.
Data Analysis. Cheng and Prusoff (1973) . In all cases, a single binding site model was chosen, unless a two-site model gave a significantly better fit by F test (p Ͻ 0.05). All nonlinear regression analyses were performed using the Prism statistical software package (version 3.0c; GraphPad Software Inc., San Diego, CA). Table 1 . Each point represents the mean Ϯ S.E of 5 to 11 replicate experiments in membranes from 4 to 11 pigs. C, specific [ 3 H]DPN binding in myenteric neuronal membranes isolated in Krebs-HEPES before centrifugation (E) or after additional centrifugation and reconstitution of membranes in either Tris (f) or Krebs-HEPES buffer (F). Data shown represent the mean Ϯ S.E.M. in the difference in radioligand binding observed in the presence and absence of 1 M naloxone of four replicate experiments with membranes from four pigs.
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To confirm that membrane isolates incubated in the two buffer solutions were equally enriched in neural elements, immunoreactivity to the neural marker GAP-43 was quantified with membrane fractions by Western blotting (Coggins and Zwiers, 1991) . Membranes isolated in both buffers yielded immunoreactive bands of approximately 48 kDa, the predicted molecular mass of GAP-43. These bands were absent in the presence of the blocking peptide, confirming the specificity of the anti-GAP-43 antiserum used. There was no significant difference in the relative density of GAP-43 immunoreactive bands with membranes incubated in Tris or Krebs-HEPES buffer (Fig. 1) Table 3 ). In contrast, the affinities of the ␦-OPR agonists deltorphin II and SNC-80 were not significantly different between these buffer conditions (Fig. 5, A 
Fig. 4. Displacement of 1 nM [ 3 H]DPN binding from myenteric neural membranes by nor-BNI (A) or GNTI (B). Assays were performed with membranes incubated in either Tris (E) or Krebs-HEPES (f) buffers. The ordinate indicates the percentage of total [
3 H]DPN binding remaining relative to the amount determined in the absence of unlabeled displacing ligands, and the abscissa indicates the log 10 molar concentration of each displacing ligand. Bold dashed and solid lines indicate the results of the nonlinear regression of the displacement assays in Tris and Krebs-HEPES buffers, respectively. The results of these regression analyses are presented in Table 2 
Discussion
Using a technique similar to that presently used in preparing myenteric neural membranes from the porcine small intestine, Allescher et al. (1989) established a crude membrane preparation of the myenteric plexus from the canine small intestine that was enriched in neuronal membranes (i.e., 
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In preparations of the myenteric plexus enriched in neural membranes from either the canine or porcine small intestine, specific binding sites for [ 3 H]DPN were detected and binding of this radioligand could be displaced by the prototypic OPR antagonist naloxone. These results strongly suggest that OPRs are expressed in crude membrane fractions from the myenteric plexus. Although we cannot exclude the possibility that opioid binding sites are expressed on the membranes of contaminating intestinal smooth muscle cells as well, the lack of detectable [ 3 H]DPN binding to purified canine smooth muscle membranes (Allescher et al., 1989) and absence of OPR immunoreactivity on intestinal smooth muscle cells in the porcine ileum (Poonyachoti et al., 2001) indicate that intestinal myocytes are not a significant source of OPR binding sites. Crude membrane fractions were used in these studies because they were highly enriched in both specific [ 3 H]STX and [ 3 H]DPN binding sites and it is possible that further purification steps might disrupt any noncovalent protein-protein interactions that may exist in the neural membranes. Because [ 3 H]DPN is an OPR antagonist ligand, its affinity for specific binding sites and those of other OPR antagonists used in this study did not change significantly in the absence or presence of physiologically relevant concentrations of Na ϩ and other ions. However, membranes incubated in Krebs-HEPES buffer manifested lower specific [ 3 H]DPN binding than those maintained in Na ϩ -free Tris buffer. This difference in binding site density was eliminated in membranes subjected to an additional centrifugation step. This observation could be due to a disruption of noncovalent associations of nonmembrane proteins present in the fractions isolated in Krebs-HEPES buffer, which may be dependent on divalent cations present within this buffer. However, there was no similar alteration in the density of specific binding sites for [
3 H]STX in membranes subjected to additional centrifugation. Additional experiments will be needed to determine whether this phenomenon represents an artifact associated with the membrane isolation procedure or an unmasking of cryptic opioid binding sites.
Naltrexone-derived ␦-and -OPR antagonists and naloxone maximally displaced [ 3 H]DPN by a similar magnitude, indicating that this portion of [ 3 H]DPN binding was to specific opioid sites. Previous immunocytochemical studies suggest that these sites are presynaptic because of the abundance of ␦-and -OPR-like immunoreactivities in nerve fibers within the myenteric plexus and intestinal smooth muscle, and the cytoplasmic localization of these receptor immunoreactivities in myenteric neurons (Brown et al., 1998; Poonyachoti et al., 2001 Poonyachoti et al., , 2002 . The naltrexone-derived ␦-OPR-selective antagonists BNTX and NTB preferentially bind to the ␦-OPR with 83-and 1000-fold greater affinity than to the -OPR, respectively (Raynor et al., 1994) . These ligands are structurally related to the -OPR antagonists GNTI and nor-BNI, which bind, respectively, to -OPRs with 390-and 2400-fold greater affinity than to ␦-OPRs (Raynor et al., 1994; Jones and Portoghese, 2000) . These antagonists displaced [
3 H]DPN from two distinct binding sites under some conditions. It is not clear whether these binding sites represent two distinct receptor entities or different isoforms of a single receptor. However, the ␦-OPR antagonists displaced specific [
3 H]DPN binding with affinities similar to their affinities for recombinant ␦-OPRs (Raynor et al., 1994; Clark et al., 1997) , whereas the low-affinity site was charac- teristic of the binding to these ligands to the -OPR (Raynor et al., 1994) or to -/␦-OPR heterodimers (Jordan and Devi, 1999) . Parallel results were obtained with the -OPR selective antagonists (Jones and Portoghese, 2000; Remmers et al., 1999) . In contrast, the peptidic ␦-OPR antagonist TIPP partially displaced [ 3 H]DPN from a single specific binding site with an affinity similar to its affinity for recombinant ␦-OPRs (Martin et al., 2002) . Its apparent interaction with a single [
3 H]DPN binding site in myenteric neural membranes might be attributable to its relatively higher selectivity for ␦-OPRs than the other ␦-OPR antagonists (Nevin et al., 1993) or to the pharmacological characteristics of the low-affinity site that may only bind neutral antagonists, of which TIPP is not (Martin et al., 2002) .
Both ␦-and -OPR agonists displaced [ 3 H]DPN from single high-affinity binding sites in myenteric neural membranes. As expected for agonists, the displacement curves of these ligands were shifted rightward in membranes incubated in Na ϩ -replete Krebs-HEPES buffer relative to those determined in membranes bathed in Na ϩ -free Tris. Agonist displacement, like that produced by TIPP, accounted for only about two-thirds of the specific [ 3 H]DPN binding. Thus, a significant amount of specific [ 3 H]DPN binding remained even in the presence of very high agonist concentrations. The extensive overlap of the predicted OPR binding domains for DPN and the other OPR ligands supports the hypothesis that these ligands interact competitively (Pogozheva et al., 1998; Filizola et al., 1999) . Noncompetitive interactions between the displacing ligand and [ 3 H]DPN may result in the partial displacement of [ 3 H]DPN from its specific binding site, if the affinity of the receptor for the radioligand is significantly reduced. Alternatively, the reported association of OPRs offers the possibility that both competitive and noncompetitive ligand interactions occur through the interaction of these receptors. As with the case of ␦-OPR antagonists, ligands acting as ␦-OPR agonists displaced [ 3 H]DPN with affinities similar to their affinities for recombinant ␦-OPR (Clark et al., 1997) . The order of affinities of these agonists in Krebs-HEPES buffer, i.e., SNC-80 Ͼ DPDPE Ͼ deltorphin II, differed from that determined in a functional assay of their actions in a porcine smooth muscle-myenteric plexus preparation in which the order of agonist potencies for inhibiting field-stimulated muscle contractions was deltorphin II Ͼ SNC-80 Ͼ DPDPE (Poonyachoti et al., 2001 ). This discrepancy between receptor affinities and potencies likely reflects differences in the efficacies of these three agonists at myenteric ␦-OPRs. Indeed, although deltorphin II exhibited the lowest relative affinity in displacing [
3 H]DPN from specific binding sites, it produced the greatest inhibitory action (Poonyachoti et al., 2001 ). The -OPR agonist U-69,593 displaced [ 3 H]DPN with a relatively lower affinity than reported previously for its binding to the cloned -OPR (Remmers et al., 1999) . This lower affinity estimate for U-69,593 is consistent with a previous determination of its affinity based on a saturation binding analysis in porcine myenteric neural membranes (Townsend and Brown, 2002) . The appearance of the additional U-69,593 binding site in membranes bathed in Tris buffer may represent the displacement of [ 3 H]DPN by this ligand from a site different from the -OPR.
The observation that saturation of the ␦-OPR binding site with DPDPE has little effect on the ability of U-69,593 to displace [ 3 H]DPN and vice versa suggests that binding sites for these two ligands represent two independent receptor subpopulations. Furthermore, in the presence of saturating concentrations of DPDPE and U-69,593, it seems that nor-BNI displaces [ 3 H]DPN from a third subpopulation of specific binding sites with relatively low affinity. From these data, we hypothesize that myenteric neurons in the porcine small intestine express both ␦-and -OPRs as well as an additional receptor subpopulation capable of binding [ 3 H]DPN that possesses some unique features. First, these latter receptors display low affinity for ␦-or -OPR agonists. Second, the peptidic ␦-OPR antagonist TIPP does not seem to bind these receptors even at very high concentrations. On the other hand, naltrexone-derived ␦-and -OPR antagonists displace [ 3 H]DPN from this receptor population with moderately high affinity. Recombinant ␦-/-OPR heterodimers have many of these same properties (Jordan and Devi, 1999) . Indeed, it is tempting to speculate that this small subpopulation of [ 3 H]DPN binding sites represents ␦-/-OPR heterodimers, especially when taken together with previous functional and immunohistochemical data from the porcine small intestine that were described above (see Introduction). Although the present study provides additional evidence in support of the hypothesis that ␦-/-OPR heterodimers are expressed in myenteric neurons, additional investigations with porcine distal small intestine preparations may provide further details on the existence and pharmacological characteristics of OPR heterodimers, their endogenous ligands, and their role in the modulation of synaptic transmission in the enteric and central nervous systems. 
